Trial Profile
A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naive Adults with Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection and Compensated Cirrhosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2019
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms EXPEDITION-8
- Sponsors AbbVie; AbbVie Germany
- 05 Nov 2019 Status changed from active, no longer recruiting to completed.
- 01 Nov 2019 Mexico is planned location as per European Clinical Trials Database record.
- 01 Nov 2019 Primary endpoint (Percentage of Participants With SVR12 in HCV GT 1,2,4,5 and 6-infected participants in the Intent-To-Treat (ITT) Population) has been met, as per the results published in the Journal of Hepatology